Sermorelin
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Sermorelin is a 29-amino-acid GHRH analog that stimulates pituitary growth hormone release when pituitary reserve is present. It was previously FDA-approved as Geref for pediatric growth hormone deficiency and diagnostic use, but the marketed product was discontinued; current adult anti-aging, body composition, recovery, or wellness use is not FDA-approved and has limited outcome evidence. Use should be clinician-supervised with IGF-1 and metabolic monitoring, and it is not appropriate in active malignancy or uncontrolled endocrine disease.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Sermorelin is a peptide most often used for stimulates endogenous gh release in supervised testing, may raise igf-1 when pituitary reserve is present, previously used for pediatric growth hormone deficiency. NutriStack rates the overall evidence as emerging. A typical adult dose is No FDA-approved wellness dose; prior pediatric treatment and diagnostic protocols used clinician-supervised injectable dosing, commonly taken as clinician-prescribed sterile injectable sermorelin acetate from a regulated pharmacy when legally appropriate. This profile indexes 3 sources.
- Injection-site reaction
- Flushing
- Headache
- Active malignancy or suspected cancer without oncology clearance
- Pregnancy and breastfeeding
The bottom line
Evidence rating emerging. Most-documented uses: stimulates endogenous gh release in supervised testing, may raise igf-1 when pituitary reserve is present, previously used for pediatric growth hormone deficiency. 3 sources indexed (1996–2013), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Sermorelin binds growth hormone-releasing hormone receptors on anterior pituitary somatotrophs, increasing cyclic AMP signaling and pulsatile endogenous GH release. GH then increases hepatic and peripheral IGF-1 production, which mediates many growth and metabolic effects. Because sermorelin depends on pituitary responsiveness, it is not equivalent to exogenous growth hormone and will not work in severe pituitary failure.1,2
Dosing & protocol.
Peptide is not orally bioavailable in ordinary capsules. Injectable use requires sterile handling and medical oversight.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Compounded sterile injectable.
Costs vary widely by pharmacy and prescription protocol; research products should not be used for human injection. Updated 2026-06-04.
Full safety detail.
Side effects
- Injection-site reaction
- Flushing
- Headache
- Dizziness
- Nausea
- Sleepiness
- Edema
- Joint pain
- Glucose intolerance in susceptible users
Contraindications
- Active malignancy or suspected cancer without oncology clearance
- Pregnancy and breastfeeding
- Uncontrolled diabetes or proliferative diabetic retinopathy without specialist care
- Severe pituitary or hypothalamic disease without endocrinology supervision
- Non-FDA-approved adult anti-aging or body composition use without clinician oversight
- Use of research-grade or nonsterile peptide products
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1- 1Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapyThorner MO et al. · Journal of Clinical Endocrinology and Metabolism · 1996
Daily GHRH(1-29) therapy increased growth velocity in children with GH deficiency.
Reviews & position papers
1- 2Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyPrakash A et al. · BioDrugs · 1999
Review summarized sermorelin biology, diagnostic use, and pediatric growth hormone deficiency data.
Reference material
1- 3Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or EffectivenessUS Food and Drug Administration · Federal Register · 2013
FDA stated discontinued Geref products were not withdrawn for safety or effectiveness reasons.
Common questions.
Quick answers about Sermorelin, drawn from the data on this page.
What is Sermorelin?
Sermorelin is a 29-amino-acid GHRH analog that stimulates pituitary growth hormone release when pituitary reserve is present. It was previously FDA-approved as Geref for pediatric growth hormone deficiency and diagnostic use, but the marketed product was discontinued; current adult anti-aging, body composition, recovery, or wellness use is not FDA-approved and has limited outcome evidence. Use should be clinician-supervised with IGF-1 and metabolic monitoring, and it is not appropriate in active malignancy or uncontrolled endocrine disease.
What is Sermorelin used for?
Commonly cited benefits of Sermorelin include: Stimulates endogenous GH release in supervised testing; May raise IGF-1 when pituitary reserve is present; Previously used for pediatric growth hormone deficiency; Adult wellness benefits are not established. NutriStack rates the overall evidence as emerging.
What is a typical dose of Sermorelin?
A typical adult dose of Sermorelin is No FDA-approved wellness dose; prior pediatric treatment and diagnostic protocols used clinician-supervised injectable dosing. The commonly recommended form is Clinician-prescribed sterile injectable sermorelin acetate from a regulated pharmacy when legally appropriate. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Sermorelin?
Reported side effects include injection-site reaction, flushing, headache, dizziness, nausea, sleepiness. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Sermorelin?
NutriStack rates this as Emerging, meaning early RCT signal, mechanistic data, or limited human evidence. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Sermorelin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.